Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world

Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved for the treatment of relapsed and refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Lei, Zhang, Jingyu, Punnoose, Elizabeth, Xiao, Zhenyu, Li, Wenjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262841/
https://www.ncbi.nlm.nih.gov/pubmed/37324548
http://dx.doi.org/10.1093/abt/tbad010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262841/
https://www.ncbi.nlm.nih.gov/pubmed/37324548
http://dx.doi.org/10.1093/abt/tbad010

Ejemplares similares